Cargando…
Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643380/ https://www.ncbi.nlm.nih.gov/pubmed/36388213 http://dx.doi.org/10.3389/fneur.2022.1016040 |
| _version_ | 1784826514588565504 |
|---|---|
| author | Lesniak, Robert K. Nichols, R. Jeremy Montine, Thomas J. |
| author_facet | Lesniak, Robert K. Nichols, R. Jeremy Montine, Thomas J. |
| author_sort | Lesniak, Robert K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9643380 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96433802022-11-15 Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk Lesniak, Robert K. Nichols, R. Jeremy Montine, Thomas J. Front Neurol Neurology Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643380/ /pubmed/36388213 http://dx.doi.org/10.3389/fneur.2022.1016040 Text en Copyright © 2022 Lesniak, Nichols and Montine. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Neurology Lesniak, Robert K. Nichols, R. Jeremy Montine, Thomas J. Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk |
| title | Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk |
| title_full | Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk |
| title_fullStr | Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk |
| title_full_unstemmed | Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk |
| title_short | Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk |
| title_sort | development of mutation-selective lrrk2 kinase inhibitors as precision medicine for parkinson's disease and other diseases for which carriers are at increased risk |
| topic | Neurology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643380/ https://www.ncbi.nlm.nih.gov/pubmed/36388213 http://dx.doi.org/10.3389/fneur.2022.1016040 |
| work_keys_str_mv | AT lesniakrobertk developmentofmutationselectivelrrk2kinaseinhibitorsasprecisionmedicineforparkinsonsdiseaseandotherdiseasesforwhichcarriersareatincreasedrisk AT nicholsrjeremy developmentofmutationselectivelrrk2kinaseinhibitorsasprecisionmedicineforparkinsonsdiseaseandotherdiseasesforwhichcarriersareatincreasedrisk AT montinethomasj developmentofmutationselectivelrrk2kinaseinhibitorsasprecisionmedicineforparkinsonsdiseaseandotherdiseasesforwhichcarriersareatincreasedrisk |